Stocks and Investing Stocks and Investing
Wed, January 11, 2023

Jasper Hellweg Maintained (UTHR) at Strong Buy with Increased Target to $300 on, Jan 11th, 2023


Published on 2024-10-28 00:52:18 - WOPRAI, Jasper Hellweg
  Print publication without navigation


Jasper Hellweg of Argus Research, Maintained "United Therapeutics Corporation" (UTHR) at Strong Buy with Increased Target from $250 to $300 on, Jan 11th, 2023.

Jasper has made no other calls on UTHR in the last 4 months.



There are 6 other peers that have a rating on UTHR. Out of the 6 peers that are also analyzing UTHR, 0 agree with Jasper's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Jasper


  • Ashwani Verma of "UBS" Initiated at Strong Buy and Held Target at $320 on, Tuesday, December 6th, 2022
  • Terence Flynn of "Morgan Stanley" Maintained at Buy with Increased Target to $330 on, Tuesday, December 6th, 2022
  • Chris Shibutani of "Goldman Sachs" Initiated at Strong Sell and Held Target at $230 on, Monday, December 5th, 2022
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $375 on, Thursday, November 3rd, 2022
  • Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $265 on, Thursday, November 3rd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $300 on, Thursday, November 3rd, 2022
Contributing Sources